Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076515 · ClinicalTrials.gov registry record · NA
Migraine Treatment With Nerivio Migra Neurostimulation Device
A NA study, sponsored by Theranica.
- Terminated
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT03076515: Clinical Trial NA study, sponsored by Theranica.
NCT03076515 is a NA study that was terminated before completion, run by Theranica. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03076515, a NA study, was terminated before completion, sponsored by Theranica.
- TERMINATED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
Primary Outcome
Percentage of participants reporting pain relief from pain (pain reduction from 3 or 2 to 1 or 0 or pain reduction from 1 to 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks
Interventions
- DEVICE Nerivio Migra neurostimulation
- DEVICE Sham Nerivio Migra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-04-02 |
| Est. Completion | 2018-04-01 |
| Phase | NA |
Why NCT03076515 stopped before completion
NCT03076515 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Nerivio Migra neurostimulation is the first listed.
NCT03076515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03076515 about?
NCT03076515 is a clinical study titled "Migraine Treatment With Nerivio Migra Neurostimulation Device". This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
What is the current status of trial NCT03076515?
This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2017-04-02. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT03076515?
The interventions under investigation include: Nerivio Migra neurostimulation (DEVICE), Sham Nerivio Migra (DEVICE).
Who is sponsoring clinical trial NCT03076515?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03076515's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI